Undetectable serum thyroglobulin in a patient with metastatic follicular thyroid cancer

Clinical Nuclear Medicine

Volumn 24, Issue 5, 1999, Pages 346-349

  Mertens, Ilse J R ^a   De Klerk, John M H ^a   Zelissen, Pierre M J ^a   Thijssen, Jos H H ^a   Sie Go, Daisy M D S ^a   Han, Shiuw H ^a   Van Rijk, Peter P ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

I 131 scintigraphy; Serum thyroglobulin; Thyroid cancer

Indexed keywords

IODINE 131; THYROGLOBULIN;

ADULT; ARTICLE; BONE METASTASIS; CASE REPORT; FEMALE; GOITER; HUMAN; SUBTOTAL THYROIDECTOMY; THYROGLOBULIN BLOOD LEVEL; THYROID FOLLICULAR CARCINOMA; THYROID SCINTISCANNING; WHOLE BODY SCINTISCANNING;

ADENOCARCINOMA, FOLLICULAR; BONE NEOPLASMS; FEMALE; HUMANS; MIDDLE AGED; THYROGLOBULIN; THYROID NEOPLASMS;

EID: 0032925590     PISSN: 03639762     EISSN: None     Source Type: Journal    
DOI: 10.1097/00003072-199905000-00011     Document Type: Article

References (14)

1. Van Herle AJ, Uller RP: Elevated serum thyroglobulin. A marker of metastases in differentiated thyroid cancer. J Clin Invest 56:272, 1975.
2. Ashcraft MW, Van Herle AJ: The comparative value of serum thyroglobulin measurements and iodine-131 total body scans in the follow-up study of patients with treated differentiated thyroid cancer. Am J Med 71:806, 1981.
3. Muller-Gartner HW, Schneider C: Clinical evaluation of tumor characteristics predisposing serum thyroglobulin to be undectetable in patients with differentiated thyroid cancer. Cancer 62:976, 1988.
4. Grant S, Luttrell B, Reeve T, et al: Thyroglobulin may be undetectable in the serum of patients with metastatic disease secondary to differentiated thyroid carcinoma. Cancer 54:1625, 1984.
5. Aiello DP, Manni A. Thyroglobulin measurement vs Iodine 131 total-body scan for follow-up of well-differentiated thyroid cancer. Arch Intern Med 150:437, 1990.
6. Schlumberger M, Tubiana M, De Vathaire F, et al: Long-term results of treatment of 283 patients with lung and bone metastases from differentiated thyroid carcinoma. J Clin Endocrinol Metab 63:960, 1986.
7. Ozata M, Suzuki S, Miyamoto T, et al: Serum thyroglobulin in the follow-up of patients with treated differentiated thyroid cancer. J Clin Endocrinol Metab 79:98, 1994.
8. Brendel AJ, Lambert B, Guyot M, et al: Low levels of serum thyroglobulin after withdrawal of thyroid suppression therapy in the follow-up of differentiated thyroid carcinoma. Eur J Nucl Med 16:35, 1990.
9. Blahd WH: Serum thyroglobulin in the management of thyroid cancer [Editorial]. J Nucl Med 31:1771, 1990.
10. Spencer C, Wang C: Thyroglobulin measurement. Techniques, clinical benefits and pitfalls. Endocrinol Metab Clin North Am 24;841, 1995.
11. Pineda JD, Lee T, Ain K, Reynolds J, Robbins J: Iodine-131 therapy for thyroid cancer patients with elevated thyroglobulin and negative diagnostic scan. J Clin Endocrinol Metab 80:1488, 1995.
12. Sherman SI, Tielens E, Sostre S, Wharam M, Ladenson P: Clinical utility of posttreatment radioiodine scans in the management of patients with thyroid carcinoma. J Clin Endocrinol Metab 78: 629, 1994.
13. Johnson MW, Morettin LB, Sarles HE, Zaharopoulos P: Follicular carcinoma of the thyroid metastatic to the kidney 37 years after resection of the primary tumor. J Urol 127:114, 1992.
14. Schlumberger M, Challeton C, De Vathaire F, et al: Radioactive iodine treatment and external radiotherapy for lung and bone metastases from thyroid carcinoma. J Nucl Med 37:598, 1996.